This Material Transfer Agreement ("MTA") has been adopted for use by the National Institutes of Health ("NIH") and the Alcohol, Drug Abuse and Mental Health Administration ("ADAMHA") in all transfers of research material ("Research Material") whether NIH or ADAMHA is identified below as its Provider or Recipient. 1. Provider agrees to transfer to Recipient's investigator named below the following Research Material: 2. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows (use an attachment page if necessary): 3. This Research Material will only be used for research purposes by Recipient's investigator in his/her laboratory under suitable containment conditions. This Research Material will not be used for commercial purposes such as screening, production or sale, for which a commercialization license may be required. Recipient agrees to comply with all Federal rules and regulations applicable to the Research Project and the handling of the Research Material. 4. In all oral presentations or written publications concerning the Research Project, Recipient will acknowledge Provider's contribution of this Research Material unless requested otherwise. To the extent permitted by law, Recipient agrees to treat in confidence, for a period of three (3) years from the date of its disclosure, any of Provider's written information about this Research Material that is stamped "CONFIDENTIAL," except for information that was previously known to Recipient or that is or becomes publicly available or which is disclosed to Recipient without a confidentiality obligation. Recipient may publish or otherwise publicly disclose the results of the Research Project, but if Provider has given CONFIDENTIAL information to Recipient such public disclosure may be made only after Provider has had thirty (30) days to review the proposed disclosure, except when a shortened time period under court order or the Freedom of Information Act pertains. 5. This Research Material represents a significant investment on the part of Provider, and is considered proprietary to Provider. Recipient's investigator therefore agrees to retain control over this Research Material, and further agrees not to transfer the Research Material to other people not under her or his direct supervision without advance written approval of Provider. Provider reserves the right to distribute the Research Material to others and to use it for its own purposes. When the Research Project is completed, or three (3) years have elapsed, whichever occurs first, the Research Material will be destroyed by Recipient or otherwise disposed of as mutually agreed by Provider and Recipient. 6. This Research Material is provided as a service to the research community. IT IS BEING SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Provider makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties. 7. When Provider is the NIH/ADAMHA: Recipient shall retain title to any patent or other intellectual property rights in inventions made by its employees in the course of the Research Project. Recipient agrees not to claim, infer, or imply Governmental endorsement of the Research Project, the institution or personnel conducting the Research Project or any resulting commercial product(s). Recipient agrees to hold the United States Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of Recipient's use for any purpose of the Research Material. 8. When Recipient is the NIH/ADAMHA: The NIH/ADAMHA shall retain title to any patent or other intellectual property rights in inventions made by its employees in the course of the Research Project. The NIH/ADAMHA are not authorized to promise rights in advance for inventions developed through this Research Project, except under a Cooperative Research and Development Agreement ("CRADA") pursuant to the Federal Technology Transfer Act of 1986. Except as may be accorded NIH/ADAMHA Patent Policy Board May 22, 1989 through Paragraph 9, below, Provider acquires no intellectual property rights under this MTA, but may apply for license rights to any patentable invention that might result from this Research Project. It is the intention of NIH/ADAMHA that Provider not be liable to NIH/ADAMHA for any claims or damages arising from NIH/ADAMHA's use of the Research Material, however, no indemnification is provided or intended. 9. Pursuant to their "Policy Statement on Cooperative Research and Development Agreements and Intellectual Property Licensing," NIH and ADAMHA may permit their investigators to enter into CRADAS (and thereby promise an option to acquire intellectual property rights) in exchange for the contribution of "essential research materials ... not otherwise reasonably available." If the Research Material transferred by this MTA is so certified below, Provider and the NIH/ADAMHA (when Recipient) investigator should submit a formal CRADA for NIH/ADAMHA approval. For nongovernmental entities that regularly provide research materials to NIH or ADAMHA, it is suggested that a master CRADA be negotiated under which a certification below will suffice to invoke the provisions of the CRADA. If Provider and Recipient otherwise decide to engage in a cooperative research or development project using the Research Material, a formal CRADA must also be negotiated. For general inquiries regarding CRADAS or NIH/ADAMHA technology transfer policies, contact the Office of Invention Development at (301) 496-0750. For receipt of Research Material under this Paragraph, when a master CRADA governing material transfers is in effect between NIH or ADAMHA and Provider, the NIH/ADAMHA investigator must identify the CRADA by NIH/ADAMHA reference number: and provide a more detailed description than in Paragraph 2, above, of the specific extent of activities within the overall Research Project to which the provisions of the CRADA will pertain (use an attachment page if necessary). Signature by the investigator and authorized official below constitutes certification that the Research Material transferred by this MTA is essential and not otherwise reasonably available for the following activities: Date: 10. This MTA shall be construed in accordance with Federal law as applied by the Federal courts in the District of Columbia. 11. Any additional terms: ADHESIONS Invention Summaries Adhesion of 'Mycoplasma pneumoniae' and 'Mycoplasma hominus' to Krivan, H. C.; Ginsburg, V.; Filed 28 Nov 88 49p PAT-APPL-7-277 634 Available from Hydrogel Adhesives and PATENT-4 339 295 Available from The invention discusses a method of bonding a material to a substrate utilizing a hydrogel adhesive and a source of microwave energy of at least 100 MHz through a waveguide. The bonding may be temporary and frangible by water or may be permanent where it is achieved in a pressure vessel. Oligomeric Adhesives PAT-APPL-7-195 000 Available from soft tissues, teeth, and bone, to other tissues and to prostheses. Examples provide details of the synthesis of the adhesives, procedures for their application and results obtained with them, with special emphasis on bonding to mineralized and soft tissues for medical, dental, and veterinary use. AIDS-HIV Acid Stable Dideoxynucleosides Active against the Cytopathic Effects of Human Immunodeficiency Virus Marquez, V. E.; Driscoll, J. S.; Tseng, C. K. H. Filed 17 Apr 87 21p PAT-APPL-7-039 402 Available from NTIS, price code: PC A02/MF A01 It is an object of the patent application to provide synthetic nucleosides which are useful in treating AIDS, to provide synthetic nucleosides which are stable in an acid environment, to provide synthetic nucleosides which inhibit the infectivity of the human immunodeficiency virus, to provide synthetic nucleosides which can be administered orally to treat acquired immune deficiency syndrome and to overcome deficiencies in the prior art, such as indicated above; and still a further object to advance AIDS therapy. AIDS (Acquired ImmunoDeficiency Syndrome) Virus Gene Expression Aldovinni, A.; DeBouck, C.; Rosenberg, M.; Wong-Staal, F. Filed 6 Nov 85 17p PAT-APPL-6-795 559 Available from NTIS, price code: PC A03/MF A01 The tat-3 gene of Human Tlymphotropic virus type III (HTLV-III) is expressed at high levels in E. coli and is reactive with antibodies induced in response to infection by HTLV-III and can induce production of antibodies which are reactive with HTLV-III. Animal Model for Diagnosing and Testing Vaccines or Therapeutic Agents against AIDS (Acquired Immunodeficiency Syndrome) Kindt, T. J. Filed 15 Mar 89 43p PAT-APPL-7-323 778 Available from Anti-Retroviral Compounds PAT-APPL-7-064 631 Available from NTIS, price code: PC A03/MF A01 The invention comprises compounds which exhibit antiretroviral activity. These compounds act to interfere with the viral life cycle, but do not exhibit the extreme toxic effects on the normal cellular processes of mammalian host cells. The invention also comprises all the novel intermediate compounds used in the synthesis of the compounds of the invention. It also comprises a method of preventing a retroviral infection in a subject or treating a subject infected with a retrovirus by administering to the subject a virus inactivating effective amount of the compounds of the invention or the pharmaceutically acceptable salts. Assay for Human Immunodeficiency Virus Chesebro, B.; Wehrly, K. Filed 15 Mar 88 31p PAT-APPL-7-168 493 Available from NTIS, price code: PC A03/MF A01 |